Keytruda

Tecentriq gains first IO approval in triple negative breast cancer

A coup for Roche in IO field dominated by Keytruda. Roche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in triple negative breast cancer. ... This is based on Keytruda’s tally of 14 FDA approvals, while the

Tecentriq combo gains European NSCLC approval

The approval will help Tecentriq compete with Merck Sharp &Dohme’s Keytruda, which has emerged as the out-and-out leader in lung cancer immunotherapy, thanks to a string of strong ... However Tecentriq is still trailing Keytruda in the vital first line

Innovent gears up for PD-1 inhibitor launch in China

BMS’ Opdivo (nivolumab) was cleared in China for previously-treated non-small cell lung cancer (NSCLC) in June 2018, while Merck’s Keytruda (pembrolizumab) got the nod from the NMPA for

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial. The relentless march of Merck &Co/MSD’s cancer immunotherapy Keytruda into mega-blockbuster territory took another step forward this week, but ... for Keytruda in second-line advanced HCC in light of the

Merck & Co to buy IO specialists Immune Design for $300m

The move is aimed at helping the pharma giant consolidate its dominance in the field of immunotherapy (IO), where its checkpoint inhibitor Keytruda leads with annual sales of $7bn in 2018.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]